Free Articles

These articles are provided free to all readers. Other free articles are available in Week in Review, In My Opinion, and Education Center. To have access to all of our articles, click here...

Recent Articles

The Week in Review: AutekBio Raises $100 Million for Biologic CMO Mar 13, 2010: AutekBio raised $100 million to build Asia’s largest biologic CMO facility in Beijing; Porton Fine Chemicals announced a $10 million funding to expand its CMO capacity; TCT Medical Technology, an OB/GYN company, booked $10 million in new capital from two Fidelity funds; EA Inc., which makes invisible dental braces, raised $6.6 million Series A from OrbiMed; Lotus Pharma (路坦制药有限公司) began building a combined office, R&D, production, and storage facility; Dr. Xiaochuan Wang, who founded Sundia MediTech (桑迪亚医药技术（上海）有限公司), was named the Asia-Pacific Entrepreneur of the Year by BioSpectrum; and WuXi PharmaTech (药明康德) reported 2009 net revenues of $270 million, an increase of 7%, and net income of $53 million. More details…

Stock Symbols: (OTCBB: LTUS) (NYSE: WX)

AutekBio to Build Largest Biologic CMO in Asia Mar 9, 2010: AutekBio, Inc., with headquarters in the Bay Area of California but operations in China, will build Asia’s largest biologic CMO facility in southern Beijing. To construct the facility, AutekBio signed a deal securing $100 million in venture capital from private and government sources. Contributing to the capital raise were SUMA Ventures and Beijing E-Town Harvest International Capital Management Corporation, Beijing’s Municipal Government’s venture capital group. More details...

The Week in Review: China Life Science to Grow 22% Per Year Through 2013 Mar 6, 2010: IMS Health predicts China’s drug market will see a 22% CAGR during 2010-2113, compared to 4%-6% worldwide; fifteen early stage China life science entrepreneurs were selected as Finalists in the SEED Competition; Chi-Med may IPO its drug development arm, Hutchison MediPharma, possibly on Nasdaq; WuXi PharmaTech (药明康德) struck a two-way pre-clinical services deal with a J&J subsidiary; aTyr Pharma received a second 18-month grant to fund research at its Hong Kong subsidiary; Sanofi-Aventis is seeking additional partnerships in China; Asymchem Labs will build another manufacturing plant in TEDA; Mindray Medical (迈瑞医疗国际有限公司), released very positive financial results and raised $150 million in new cash; Biostar Pharma expects a 35% increase in 2010 revenues; and Kalen Biomedical found a China distribution partner for its research products. More details…

Stock Symbols: (NYSE: RX) (AIM: HCM) (NYSE: WX) (NYSE: JNJ) (NYSE: SNY) (NYSE: MR) (OTCBB: BSPM)

SEED Competition for China Life Science Announces Finalists Mar 5, 2010: Fifteen entrepreneurs from a broad spectrum of life science fields were selected as Finalists in the SEED Competition, which makes them eligible to compete for the Grand Prize of 300,000 RMB ($45,000). The awards were made at the SEED Finalist Coaching Day event held in Shanghai’s Zhangjiang Hi-Tech Park earlier this week. Over 140 people attended the event. Roche, OrbiMed, and McKinsey organized the SEED competition, which was managed and presented by ChinaBio® Accelerator. More details...

Stock Symbol: (SW: ROG)

The Week in Review: New Deals in China Life Science Feb 27, 2010: Merck, Lilly and Pfizer will work together to compile a pharmacogenomic gastric and lung cancer database in Singapore; the PRC authorized 37 billion RMB ($5.5 billion) to increase access to medical care; WuXi PharmaTech (药明康德) is expanding services to keep revenues growing; WuXi also received AAALAC Accreditation for its new Suzhou tox lab; China Cord Blood Corp. paid $20.5 million for a 20% equity interest in Shandong Cord Blood Bank; Fosun Pharma will invest $9.7 million into Biosino Bio-Technology; Beijing Shenghong Biotech paid $4.1 million for four new drug projects; Lundbeck authorized Teva Pharma to distribute its Parkinson’s treatment in China; China Aoxing will collaborate with QRxPharma Limited to develop its narcotic combination in China; and Indian CMO Dishman hopes to have its Shanghai facility operational by September 2010. More details…

Stock Symbols: (NYSE: MRK) (NYSE: LLY) (NYSE: PFE) (NYSE: WX) (NYSE: CO) (CPH: LUN) (NSDQ: TEVA) (OTCBB: CAXG) (ASX: QRX and OTCQX: QRXPY)

The Week in Review: 3SBio and Ascentage Form Cancer Partnership Feb 13, 2010: 3SBio (沈阳三生制药) and Ascentage Pharma will develop targeted cancer therapeutics focusing on programmed cell death; Allele Biotech was granted a China patent with far-reaching claims for RNAi; Private equity investors in the west currently find emerging markets, especially China, an attractive investment; Gorbec Pharm will open a GMP-compliant analytical laboratory in Yantai; NeoStem priced a public offering of 5,000,000 shares; 3SBio in-licensed the China rights to a phosphate binder for dialysis patients; Simcere Pharma (先声药业) received SFDA approval to market the flu drug Relenza; Celsis In Vitro Technologies found a China distributor for its drug discovery products; OrbusNeich began a China clinical trial of its Genous Bio-engineered R stent; and Tianyin Pharma reported positive results for its fiscal Q2. More details...

Stock Symbols: (NSDQ: SSRX) (NYSE Amex: NBS) (NYSE: SCR) (NYSE Alternext: TPI)

The Week in Review: New Investments in China Life Science Feb 6, 2010: BioMarin Pharma will pay up to $96 million to acquire LEAD Therapeutics, which is connected to ShangPharma; Tongjitang Chinese Medicines will acquire Guiyang Liquor Factory for $17.7 million; Zhejiang Hisun Pharma will make a $10 million investment in Sagent Pharma of the US; Sanofi-Aventis formed a consumer healthcare joint venture with Minsheng Pharma; China Medicine Corp. closed a previously announced $70 million private placement; Huifeng Bio-Pharma predicts 2010’s revenues will jump 50% or more; Achillion Pharma out-licensed the China rights for a hepatitis B treatment to GCA Therapeutics; Response Biomedical signed up a second partner to market its diagnostic products in China; Sinobiopharma’s most important product is now covered by China’s basic health insurance plan; NeoStem’s China subsidiary received manufacturing approval for its new facility; and finally, China will establish pilot programs to get hospital reform underway. More details...

Stock Symbol: (NSDQ: BMRN) (NYSE: TCM) (SHA: 600267) (NYSE: SNY) (OCTBB: CHME) (OTCBB: HFGB) (NSDQ: ACHN) (TSX: RBM, OTCBB: RPBIF) (OTCBB: SNBP) (NYSE Amex: NBS)

The Week in Review: Suzhou Nanomed Funded by Softbank Jan 30, 2010: Suzhou Natong BioNanotechnology signed a funding agreement with Softbank’s SB China Venture Capital (SBCVC); China exchanges raised more money in IPO transactions during 2009 than their US counterparts; Covance has begun construction on a pre-clinical facility near Shanghai; Sinovac (北京科兴生物制品有限公司) raised $54 million in a secondary offering; NeoStem's China subsidiary was granted SFDA approval for an anti-ulcer drug; Sinobiopharma was given production approval for a blood pressure medication; China Aoxing Pharma completed a Phase III trial of a synthetic oral narcotic; Novo Nordisk submitted its type 2 Diabetes drug for SFDA approval; and Bayer Schering is beginning a Phase IV trial of a blood pressure drug in China. More details...

Stock Symbol: (NYSE: CVD) (NSDQ: SVA) (NYSE Amex: NBS) (OTCBB: SNBP) (OTCBB: CAXG) (NYSE: NVO)

Suzhou Nanomed Secures VC Funding from Softbank Jan 29, 2010: Suzhou Natong BioNanotechnology Ltd. (Nanomed) announced it has signed a funding agreement with Softbank’s SB China Venture Capital (SBCVC). Nanomed had previously won the “Most Promising Company” Award in the Medical Device field at the BioBay Investor Forum co-organized by ChinaBio® LLC and the Suzhou BioBay life science park in August 2009. Financial details of the funding were not disclosed. More details...

The Week in Review: China Pharma Investment, Company Progress Jan 23, 2010: Pfizer has built a Shanghai-based business development team to take advantage of the consolidation it expects over the next few years; the Changzhou Biopharmaceutical Incubator began construction of its $76 million project; Morningside Asia Venture will form a China JV with Can-Fite BioPharma to develop a liver cancer drug; China Pharma Holdings has asked for SFDA approval of a generic anti-hypertension drug; China Sky One Medical (中国天字一号医药公司) will turn its focus toward injected generic western drugs; Sinovac Biotech (北京科兴生物制品有限公司) expects to beat 2009 forecasts and will issue additional shares; Sinobiopharma reported greatly improved financial results for its Q2; Shandong Luoxin Pharma listed its ADRs on the QX tier of the OTC Exchange; and Burdica Biomed will have Sinopharm register its products in China and distribute them. More details...

Stock Symbol: (NYSE: PFE) (TASE: CFBI) (NYSE: CPHI) (NSDQ: CSKI) (NSDQ: SVA) (OTCBB: SNBP) (HKEX: 8058; OTCQX: SLUXY)